PDCD1 and melanoma: Overall, patients who had tumors bearing a high frequency of somatic mutations like melanoma, NSCLC, and MSI-H colorectal cancer were significantly more likely to achieve clinical benefit from checkpoint blockade including CTLA-4 and PD-1 inhibitors [46–50].